Improving HPV vaccination rates through enhanced physician communication
Official title: PCOM2 - The Physician Communication Intervention, Version 2.0" for "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake"
Run by University of Colorado, Denver · NCT05336240 · Data updated 2026-11-12
This study is testing a new online way for doctors to talk to teens about getting the HPV vaccine to see if it helps more of them get vaccinated compared to the usual method.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 9 Years to 17 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 2 sites (Aurora, Colorado and 1 other locations) |
| Status | Recruiting |
| Started | November 15, 2023 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | August 26, 2024 |
| Trial ID | NCT05336240 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are parents of adolescents aged 9-17 years who are receiving care at participating clinics.
✕Probably not a fit
Patients who do not have adolescents in the specified age range or are not receiving care at enrolled clinics will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop and evaluate a virtual version of the Physician Communication Intervention (PCOM) to improve HPV vaccination rates among adolescents. By comparing the efficacy of the new PCOM-Virtual intervention to the original PCOM-Standard, the researchers will assess how well each approach increases vaccination rates. The study will utilize mixed methods to understand the contextual factors that influence the effectiveness of these interventions. Ultimately, the goal is to create a user-friendly intervention that can be widely implemented in primary care settings to enhance adolescent preventive health services.
Why it matters
Potential benefit: If successful, this intervention could significantly increase HPV vaccination rates among adolescents, reducing their risk of HPV-associated cancers and diseases.
How similar studies have gone: Previous studies using similar communication interventions have shown success in increasing HPV vaccination rates, indicating that this approach has potential.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Parents: Have an adolescent between the ages of 9-17 years old and receiving adolescent care at an enrolled clinic * Providers: All providers at participating study practices will be eligible to participate. Exclusion Criteria: * Parents: Does not have an adolescent between the ages of 9-17 years old and is not receiving adolescent care at an enrolled clinic * Providers: Providers who are not at participating study practices
Where it's running
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States Recruiting -
University of Kansas Medical Center
Wichita, Kansas, United States Recruiting
Study contacts
- Principal investigator: Sean O'Leary, MD, MPH — University of Colorado, Denver
- Study coordinator: Christine Spina, MSPH
- Email: CHRISTINE.BABBEL@CUANSCHUTZ.EDU
- Phone: 303.724.0906
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of cervical cancer after HPV detection in healthy women
This study tests how likely it is for cervical cancer to develop after different HPV detection patterns in healthy women who undergo HPV-based screening.
-
Longevity Metrics AI/ML Development Study
Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.
-
Health Ahead: Comparing AI vs. Humans for Preventive Health Screening
This study tests AI-assisted screening interpretation against human-only reads to see if automated screening can match or improve current practice for adults, especially in underserved areas.
-
Dysplasix™ intravaginal suppositories for women with high‑risk HPV and mild cervical cell changes
This trial tests whether nightly Dysplasix™ vaginal suppositories can clear high‑risk HPV and help mild cervical cell changes (ASC‑US or LSIL) in adult women.
-
At-home HPV self-collection kits for cervical cancer screening
We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.
-
Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV
This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.